GlassScriptPhysician profile
Pamraj Sharma
NPI 1295229045
$1,482.22
in general payments reported to CMS, 2019-2025
24 companies · $460 in 2025
The $460 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $106 · 2021: $138 · 2022: $31.20 · 2023: $232 · 2024: $178 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $359.94 | 2019-2025 | Jot Dx |
| Ucb, INC. | $136.53 | 2020-2023 | Briviact |
| Ceribell, INC. | $117.16 | 2025 | Pocket Eeg Device |
| Csl Behring | $113.81 | 2019 | |
| Abiomed | $93.36 | 2025 | |
| Abbvie INC. | $81.42 | 2021-2025 | Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $72.78 | 2021 | |
| Merz North America, INC. | $60.33 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $51.12 | 2022-2024 | Ultomiris |
| Pfizer INC. | $50.74 | 2023-2024 | |
| Genzyme Corporation | $41.28 | 2019-2021 | |
| Acorda Therapeutics, INC | $38.77 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $32.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.14 | 2023 | Xarelto |
| Livanova USA, INC. | $31.09 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $21.19 | 2019 | |
| Boston Scientific Corporation | $20.98 | 2023 | Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $20.92 | 2023 | Andexxa |
| Genentech USA, INC. | $20.55 | 2025 | Tnkase |
| Merck Sharp & Dohme LLC | $18.96 | 2024 | Zerbaxa, Dificid, Recarbrio |
| Akcea Therapeutics, INC. | $17.13 | 2020 | |
| Jazz Pharmaceuticals INC. | $17.08 | 2022 | |
| Lilly USA, LLC | $16.47 | 2024 | Amyvid |
| Celgene Corporation | $16.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamraj Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.